Full-Time

Verification & Validation Lead

Capstan Medical

Capstan Medical

51-200 employees

Catheter-based heart valve replacement via robotics

No salary listed

Santa Cruz, CA, USA + 1 more

More locations: Mountain View, CA, USA

Hybrid

Possible future option to work one day per week from satellite office in Los Altos, CA.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Software Testing
Risk Management

Get referred to Capstan Medical

See people who can refer or advise you

Requirements
  • BS in Computer Science, Software Engineering, Biomedical Engineering, or equivalent; MS preferred
  • 5-10 years of experience in software verification and validation, test engineering, or software quality in the medical device industry
  • Demonstrated leadership experience—formal or informal—in guiding V&V activities and mentoring engineers
  • Comfortable being hands-on: you’re energized by executing tests yourself, not just delegating
  • Track record of delivering verification evidence packages for regulatory submissions
  • Experience working cross-functionally to influence requirements, risk management, and design decisions
  • Ability to work in a hybrid environment, onsite 3 days a week at our Santa Cruz, CA office. In the future, there will be an option to work one day from our satellite office in Los Altos, CA.
Responsibilities
  • Own the V&V strategy for the robotic surgical platform, defining the approach for software, system, and design validation activities
  • Plan and manage V&V project timelines, resource allocation, and deliverables aligned with program milestones and regulatory submissions
  • Establish and continuously improve V&V processes, templates, and infrastructure to scale with the organization
  • Mentor and guide V&V engineers, fostering technical growth and maintaining high standards for verification evidence
  • Partner with systems engineering to influence system requirements, ensuring they are verifiable, traceable, and properly decomposed from user needs
  • Collaborate with regulatory affairs to shape submission strategy and ensure V&V deliverables meet FDA and notified body expectations
  • Work with risk management to ensure verification activities adequately address risk controls and software safety classification per IEC 62304 and ISO 14971
  • Engage with clinical and human factors teams to plan and execute design validation activities including simulated use and clinical evaluations
  • Represent V&V in design reviews, providing expert input on requirement clarity, testability, and verification approach
  • Design and execute software verification test protocols demonstrating compliance with system and software requirements per IEC 62304
  • Personally execute test cases at the bench—we don’t have a separate test execution team, and all engineers participate in running DV protocols
  • Own requirements traceability matrices linking User Needs through system requirements, software requirements, and verification evidence
  • Develop and execute test strategies spanning unit, integration, and system-level verification for real-time robotic control software
  • Author and review test protocols and reports that withstand regulatory scrutiny from FDA and notified body reviewers
  • Drive adoption of automated test frameworks that integrate with CI/CD pipelines while maintaining design control compliance
Desired Qualifications
  • Experience with robotic systems, motion control, or real-time embedded software testing
  • Experience building or scaling V&V functions in a startup or growth-stage environment
  • Experience with test automation frameworks and scripting (Python preferred)
  • Experience with test fixtures, hardware-in-the-loop testing, or bench test development
  • Knowledge of FDA 21 CFR 820, ISO 13485, and EU MDR requirements
  • Track record of successful FDA 510(k), De Novo, or PMA submissions
  • Exposure to usability engineering (IEC 62366) and design validation methodologies

Capstan Medical develops catheter-based heart valve replacement solutions that use surgical robotics to guide valve implants through small blood vessels, avoiding open-heart surgery. Its system combines implants, delivery catheters, and robotic navigation to treat mitral and tricuspid valve disease with minimally invasive methods. The company differentiates itself by integrating robotic guidance with catheter delivery and by pursuing less invasive replacements for structural heart disease, evidenced by the world’s first robotic-catheter mitral valve replacement in humans. Its goal is to provide safer, quicker-recovery treatments for patients with valve disease.

Company Size

51-200

Company Stage

Series C

Total Funding

$141.4M

Headquarters

Santa Cruz, California

Founded

2020

Get referred to Capstan Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • December 2024: Capstan raised $110 million Series C led by Eclipse, funding trials.
  • March 2025 human implant success de-risks the platform before pivotal trials.
  • ClinicalTrials.gov shows five-year follow-up across Australia, Chile, and New Zealand, signaling serious international execution.

What critics are saying

  • NCT06600191 remains first-in-human, so one safety failure can freeze financing and adoption.
  • TMVR excludes many patients with poor anatomy, limiting scale versus Abbott MitraClip and Edwards programs.
  • No FDA-approved transcatheter mitral valve replacement exists; prolonged trials burn cash and invite acquisition pressure.

What makes Capstan Medical unique

  • March 6, 2025: first robotic-catheter mitral replacements in humans, a rare structural-heart milestone.
  • Capstan merges surgical robotics with transcatheter delivery, unlike standard TEER or manual TMVR approaches.
  • The company targets both mitral and tricuspid disease from Santa Cruz, near Silicon Valley talent.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

3%

2 year growth

28%
VNTR
Feb 21st, 2026
Pharma giants return to the M&A table: what $38B in biotech exits signals.

Pharma giants return to the M&A table: what $38B in biotech exits signals. February 21, 2026 Roughly $38 billion in announced and completed biotech M&A across 2024 and early 2025 marks one of the strongest acquisition cycles since the pre-pandemic boom, even as AI absorbs most of the market's mindshare. While capital continues to chase foundational AI models and infrastructure, large pharmaceutical companies are quietly reasserting themselves as the most reliable source of liquidity for life sciences investors. The contrast is sharp: public enthusiasm has shifted to compute and chips, but strategic buyers in biotech are writing substantial checks for assets that show clinical maturity and clear paths to differentiation. Several transactions underscore the scale and seriousness of this renewed activity. Eli Lilly's $2.4 billion acquisition of Orna demonstrated major pharma's willingness to pay premium valuations for emerging in vivo technology platforms rather than wait for later-stage de-risking. AbbVie reinforced the trend with its $2.1 billion purchase of Capstan, a move that signals continued appetite for next-generation delivery systems capable of supporting pipeline expansion. Both deals highlight a pattern: strategic acquirers are targeting platforms with clinical validation and enough optionality to influence multi-year R&D planning. The most significant transaction in the recent wave came from Johnson & Johnson, which executed a $3.05 billion all-cash acquisition of Halda. The cash-only structure is notable. In an environment where equity markets remain choppy and biotech IPOs are rare, cash consideration provides a clear and immediate exit - precisely what many investors have been waiting for after two years of constrained liquidity. It also reiterates that large pharma balance sheets remain strong and that buyers prefer straightforward transactions without contingent components. These deals are occurring even as the broader financing environment remains uneven. Venture funding share for biotech has declined relative to AI, and public markets have yet to fully reopen for early-stage or mid-cap life sciences companies. But M&A, not IPOs, is currently the mechanism delivering real liquidity. For investors, that distinction matters more than sector-level sentiment. The takeaway is direct: strategic acquirers are active, capital is being deployed, and exits are happening at meaningful valuations. The window is selective, but it is open. For portfolios holding clinical-stage assets or differentiated platforms, the current cycle offers a viable path to liquidity - and one that appears to be strengthening rather than fading. February 21, 2026 VNTR Research Team

WTWH Media LLC
Feb 23rd, 2025
Capstan Medical CEO on Nitinol, Funding

Capstan Medical's CEO, Maggie Nixon, discusses the company's work with nitinol in developing mitral heart valve implants and their collaboration with suppliers like Admedes. She highlights the importance of partnerships in manufacturing and shares leadership insights since becoming CEO. Capstan, which emerged from Occam Labs, has grown significantly. Nixon also praises Intuitive Ventures for their continued investment and advises engaging with them at conferences for potential deals.

Lookout Local, Inc.
Dec 11th, 2024
Santa Cruz medtech company raises $110 million for its efforts to treat heart disease

Santa Cruz-based Capstan Medical is poised to take the next step in its treatment of heart valve disease, announcing a new $110 million funding round as it prepares for patient trials next year.

HIT Consultant
Dec 11th, 2024
Capstan Medical Secures $110M for Heart Valve Tech

Capstan Medical has raised $110M in a Series C funding round led by Eclipse, with participation from Yu Galaxy, Intuitive Ventures, and Gideon Strategic Partners. The funds will advance their minimally invasive heart valve treatment, which includes novel implants, advanced catheter technology, and a robotic platform. The investment will accelerate clinical trials, expand R&D, and scale operations to improve treatment options for heart valve disease.

HIT Consultant
Dec 11th, 2024
Capstan Medical Raises $110M to Advance Minimally Invasive Heart Valve Treatment

- Capstan Medical, a medical technology company developing innovative solutions for heart valve disease secures $110M in a Series C funding round led by Eclipse with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.